Oncology drugs growing stronglyNew cancer therapies sales could total $230 billion by 2024, which will be a fifth of all drug sales, according to analyst firm Evaluate Pharma, Handelsblatt reported on Monday in a review on the American Society of Clinical Oncology (ASCO) annual meeting in Chicago (p22-23).
Higher drug prices in the U.S. due to older drugsThe increase in U.S. drug prices is primarily due to older drugs and not so much to new therapies, FAZ reported on Thursday (p16).
McKinsey could have contributed to aggressive opioid marketing strategiesU.S.-based consultancy McKinsey could have contributed to aggressive opioid marketing strategies for Purdue, manufacturer of top-selling Oxycontin (oxycodone), FAZ reported on Monday (p18).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.